GlassScriptPhysician profile
Julie L Lundy
NPI 1992919682
$8,782.98
in general payments reported to CMS, 2019-2025
48 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $857 · 2021: $1,216 · 2022: $1,431 · 2023: $1,711 · 2024: $1,158 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,941 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,941.27 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,171.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,022.30 | 2020-2025 | |
| Pfizer INC. | $1,015.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $896.68 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $783.14 | 2019-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $378.36 | 2019-2025 | Belsomra, Steglatro, Gardasil 9 |
| Lilly USA, LLC | $369.26 | 2020-2025 | Jardiance, Mounjaro, Trulicity |
| Allergan, INC. | $262.53 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $255.88 | 2019-2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $249.53 | 2019-2022 | |
| Astellas Pharma US INC | $248.29 | 2023-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $190.62 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.29 | 2019-2024 | Jardiance, Synjardy |
| Teva Pharmaceuticals USA, INC. | $148.88 | 2022-2024 | Ajovy, Austedo, Austedo Xr |
| Amarin Pharma, INC. | $123.29 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Lundy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.